Peptide Comparison
TB-500 vs Wolverine
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
TB-500 has stronger documented evidence (Anecdotal + Animal Studies) than Wolverine (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, TB-500 is the safer pick. Wolverine may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| TB-500 | Wolverine | |
|---|---|---|
| Class | Thymosin β4 fragment; tissue repair | Combination peptide stack |
| Drug class | Tissue Repair | Tissue Repair |
| Mechanism | Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration | Combined cytoprotective + actin regulation (see individual entries) |
| Route | SC / IM | SC / IM |
| Half-life | Several hrs to days (tissue uptake) | See individual peptides |
| Dosage (research) | 2-2.5 mg SC/IM 2x weekly for 4-6 week load; then 2 mg monthly | BPC 250-500 mcg + TB 2 mg SC daily or split weekly |
| Evidence tier | Anecdotal + Animal Studies | Anecdotal |
| Research depth | 32 indexed | 1 indexed |
| Availability | Compounding Restricted | Compounding Restricted |
| Reported risks | WADA-banned; limited human data; injection site pain; lethargy; theoretical proliferation concerns | Combined risk profile of both; no combination safety trials |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick TB-500 or Wolverine?
TB-500 has stronger documented evidence (Anecdotal + Animal Studies) than Wolverine (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, TB-500 is the safer pick. Wolverine may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between TB-500 and Wolverine?
TB-500 is classed as Thymosin β4 fragment; tissue repair; Wolverine is classed as Combination peptide stack. Reported mechanism: TB-500, Binds and sequesters G-actin; promotes actin polymerization; upregulates angiogenesis and cell migration; Wolverine, Combined cytoprotective + actin regulation (see individual entries). Reported half-life: TB-500, Several hrs to days (tissue uptake); Wolverine, See individual peptides. Routes in published studies: TB-500, SC / IM; Wolverine, SC / IM.
Which has stronger evidence, TB-500 or Wolverine?
TB-500 and Wolverine sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. TB-500 is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 32 indexed studies. Wolverine is graded Anecdotal, with 2 cited sources on its reference page and 1 indexed studies.
Which is more accessible, TB-500 or Wolverine?
Neither TB-500 nor Wolverine is an FDA-approved drug. Catalog status: TB-500, Compounding Restricted; Wolverine, Compounding Restricted. FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against, 1 abstention on 23 July 2026 to recommend TB-500 for the 503A Bulks List; the vote is advisory and changes nothing by itself.
Are TB-500 and Wolverine ever combined?
TB-500 and Wolverine appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…